RxDoctor Payments Data

Sarah Harder

Family · Knoxville, TNNPI 1619410099

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.4% of the total across 815 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,067, 4.5 times the $1,129 reported in 2021. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,367in general payments, 2019–2025

Across 815 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AstraZeneca$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$1K
  • Amgen$870
  • Merck$861
  • plus $13K from 54 others

What the payments were for

  • Food & beverage$18,47995%
  • Education$8885%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson46$1,549
AstraZeneca(2 entities)46$1,219
E.r. Squibb & Sons, L.L.C.43$1,039
Novartis55$1,004
Amgen32$870
Merck38$861
Pfizer41$834
Genentech USA, Inc.35$720
Incyte Corporation26$718
Gilead(2 entities)25$691
Regeneron Healthcare Solutions, Inc.22$647
Sanofi25$639
Bristol Myers Squibb39$610
Astellas Pharma US Inc26$560
Seagen Inc.22$469
AbbVie18$460
Eisai Inc.22$455
GSK21$443
Takeda Pharmaceuticals U.S.A., Inc.19$438
Bayer19$381
Lilly USA, LLC17$355
Puma Biotechnology, Inc.16$337
Karyopharm Therapeutics Inc.11$309
Daiichi Sankyo Inc.11$283
Caris MPI, Inc.9$275
AVEO Pharmaceuticals, Inc.8$262
Array Biopharma Inc8$171
Jazz Pharmaceuticals Inc.4$164
Iovance Biotherapeutics, Inc.2$160
Deciphera Pharmaceuticals Inc.6$156
Exelixis Inc.6$145
Beigene USA, Inc.6$141
Myriad Genetic Laboratories, Inc.7$129
Heron Therapeutics, Inc.1$125
G1 Therapeutics, Inc.5$111
Blueprint Medicines Corporation5$110
Mirati Therapeutics, Inc.4$107
Sobi, Inc5$107
Genmab U.S., Inc.5$105
Boehringer Ingelheim5$104
EMD Serono, Inc.5$102
Servier Pharmaceuticals LLC4$88
Morphosys, US Inc.5$86
Novocure Inc.5$83
Stemline Therapeutics Inc.3$74
Beone Medicines USA, Inc.3$70
Ipsen Biopharmaceuticals, Inc3$63
Tersera Therapeutics LLC3$59
Pharmacosmos Therapeutics Inc.3$55
Springworks Therapeutics, Inc.2$50
Geron Corporation2$49
Taiho Oncology, Inc.3$47
ADC Therapeutics America, Inc.2$41
Kyowa Kirin, Inc.2$37
Janssen Scientific Affairs, LLC1$35
Immunogen, Inc.1$29
Syndax Pharmaceuticals, Inc.1$27
Pharmaessentia USA Corporation1$24
Pharmacyclics LLC, An Abbvie Company1$22
Apellis Pharmaceuticals, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,367 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$7,241
Medicare patients
50
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$12,522
Megestrol Acetate18$1,307
Oxycodone Hcl48$993
Morphine Sulfate ErMorphine Sulfate23$858
Tramadol Hcl24$635
Gabapentin53$633
Letrozole23$453
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$451
Ondansetron OdtOndansetron32$374
Prochlorperazine Maleate33$373
Dexamethasone17$323
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$156
Methylprednisolone17$124
Lorazepam22$67
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$834$12,52216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →